logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Vimta Labs Ltd

Vimta Labs

Small Cap•1,428 Employees•IPO 1993
Current Price
₹439.45
-12.6 (-2.79%)Updated
NSE :VIMTALABS
BSE :524394
Sector :Life Sciences Tools & Services
Today's Range
₹424.90
₹439.45
union icon
₹445.95
52 Week Range
52W Low₹408.10
52W High₹1173.85
₹439.45
union icon
Downside7.68%
Upside167.12%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹2,031 Cr
Market Cap
Total market value of company
P/E Ratio
25.83
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
7.56
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹17.47
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
9.62%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
17.60%
ROCE
Return on Capital Employed. >15% is good
Net Margin
20.49%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
36.95%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
13.75%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
20.60%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
43.00%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.02
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹85.19
Book Value
Net asset value per share
Dividend Yield
0.22%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
36.00%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Robust ROCE of 17.60% highlights effective capital utilization and profit generation.
  • •Impressive quarterly profit growth of 43.00% and sales surge 20.60%.

Weaknesses

5 points
  • •High P/E ratio of 49.30 suggests potential overvaluation compared to sector.
  • •Relatively low promoter holding at 36% raises concerns about commitment.

Opportunities

3 points
  • •Expanding 'Healthcare Research Analytics & Technology' sector driven by increased R&D spending.
  • •Growing global demand for specialized analytical services in pharma and biotech.

Threats

4 points
  • •Intense competition from larger players could pressure pricing and market share.
  • •Evolving stringent regulatory landscape in healthcare poses continuous compliance and operational risks.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
Harriman Vungal
06 Feb 202512 Feb 202517.76 L
1,200
-SELL
Harriman Vungal
06 Feb 202512 Feb 202517.77 L
975
₹1,038SELL
Harriman Vungal
12 Feb 202517 Feb 202517.73 L
2,900
₹1,083.66SELL
VASIREDDI VEERABHADRA PRASAD
28 May 202502 Jun 20255.14 L
9.50 L
₹976.4SELL
SUJANI VASIREDDI
28 May 202502 Jun 20254.16 L
3.50 L
₹976.4BUY
RAJYA LAKSHMI VASIREDDI
28 May 202502 Jun 20256.02 L
6.00 L
₹976.4BUY

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹490.73+₹51.28+11.67%
R3₹469.68+₹30.23+6.88%
R2₹457.82+₹18.37+4.18%
R1₹448.63+₹9.18+2.09%
PIVOT₹436.77-2.68-0.61%
CURRENT₹439.45--
S1₹385.48-₹53.97-12.28%
S2₹406.53-₹32.92-7.49%
S3₹415.72-₹23.73-5.40%
S4₹427.58-₹11.87-2.70%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
1.85L
(02 Mar 2026)
-34.8% vs avg
Delivery %
48.2%
(02 Mar 2026)
+15.9% vs avg
Avg Volume (20D)
2.84L
(03 Feb - 02 Mar)
20-day average
Avg Delivery %
32.3%
(03 Feb - 02 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Divis Laboratories Ltd
1.64L ₹ Cr
Best Profit Growth
Brooks Laboratories Ltd
498.00 %
Highest Dividend Yield
Windlas Biotech Ltd
1.29 %

Peer Comparison

Company Name
AKUMS
Akums Drugs & Pharmaceuticals Ltd
BOROSCI
Borosil Scientific Ltd
BROOKS
Brooks Laboratories Ltd
DCAL
Dishman Carbogen Amcis Ltd
DIVISLAB
Divis Laboratories Ltd
FABTECH
INDGN
Indegene Ltd
INNOVACAP
Innova Captab Ltd
SUVEN
Suven Life Sciences Ltd
TARSONS
Tarsons Products Ltd
WINDLAS
Windlas Biotech Ltd

About

VIMTALABS

Vimta Labs Ltd

Vimta Labs Limited is a prominent contract research and testing services provider operating both domestically in India and internationally. Their core business revolves around offering comprehensive support to a diverse range of industries, enabling them to streamline their research, development, and quality control processes.

A significant portion of Vimta Labs' services centers on the biopharmaceutical sector. They provide crucial support throughout the drug lifecycle, encompassing preclinical and clinical research phases, as well as analytical services. This allows biopharmaceutical companies to outsource complex research tasks, benefiting from Vimta's expertise and infrastructure.

Beyond pharmaceuticals, Vimta Labs caters to the needs of medical device companies by offering preclinical research and testing services. This ensures the safety and efficacy of medical devices before they reach the market. Their services extend to agrochemical and specialty chemical companies, assisting with contract research and testing critical for product development and regulatory compliance.

Food safety and quality assurance forms another important pillar of Vimta Labs' business. They provide comprehensive testing and analytical development services to a broad spectrum of stakeholders in the food industry, including manufacturers, processors, and regulatory bodies. This includes testing for various food products and materials.

Furthermore, Vimta Labs offers environmental regulatory services, crucial for industries facing environmental impact assessments and post-project monitoring requirements. This support extends to a wide range of sectors such as power, infrastructure, cement, oil and gas, and mining. They also provide EMI/EMC testing for electronic and electrical products and components.

In summary, Vimta Labs provides a broad portfolio of testing and research services across numerous sectors. Their diverse clientele includes those in agriculture, biologics, personal care, medical devices, specialty chemicals, food, electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, and environmental sectors. This wide-ranging expertise and established presence make Vimta Labs a significant player in the contract research and testing landscape.

COMPANY FACTS - VIMTALABS

Registered Address

Plot No.141/2 & 142, IDA, Phase-II, Cherlapally

Hyderabad

TELANGANA

IN

Tel: 914027264141

Website:https://vimta.com/

Investor Relations:http://www.vimta.com/financials
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Life Sciences Tools & Services

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 1,428

IPO Date: 13/09/1993

MANAGEMENT - VIMTALABS

Dr. Sivalinga Vasireddi

Executive Chairman of the Board

Shri. Siva Rama Kambhampati

Chief Financial Officer

Mrs. Sujani Vasireddi

Company Secretary, Compliance officer

Ms. Harita Vasireddi

Managing Director, Executive Director

Mr. Satya Neerukonda

Executive Director

Shri. Harriman Vungal

Executive Director - Operations

Mr. Sanjay Dave

Non-Executive Independent Director

Mr. Purnachandra Gutta

Non-Executive Independent Director

Mr. Yadagiri Pendri

Non-Executive Independent Director

Smt. Yalamanchili Rani

Non-Executive Independent Director

Investor Questions Answered

Vimta Labs Ltd (VIMTALABS) Stock FAQs

Get answers to the most common questions about Vimta Labs Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Vimta Labs Ltd (VIMTALABS) is ₹439.45. Today, the stock has declined by ₹12.60 (2.79%), trading in a range of ₹424.9 to ₹445.95. The stock opened at ₹426.85 with a trading volume of 1,85,306 shares.
Vimta Labs Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,031 crores, P/E ratio of 25.83, ROE of 9.62%, and ROCE of 17.60%. The dividend yield stands at 0.22%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Vimta Labs Ltd (VIMTALABS) is ₹1,173.85, while the 52-week low is ₹408.1. Currently trading at ₹439.45, the stock is 4.1% away from its 52-week low and 62.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Vimta Labs Ltd stock at ₹439.45 depends on multiple factors. The stock is currently trading with a P/E ratio of 25.83 and P/B ratio of N/A. Today's performance shows a loss of 2.79%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Vimta Labs Ltd offers a dividend yield of 0.22%, which means for every ₹100 invested at the current price of ₹439.45, you can expect to receive approximately ₹0.22 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Vimta Labs Ltd's key financial metrics include: P/E Ratio: 25.83, P/B Ratio: N/A, ROE: 9.62%, ROCE: 17.60%, Dividend Yield: 0.22%, EPS: ₹17.47, Book Value: ₹85.19, Debt-to-Equity: 0.02, and Current Ratio: N/A. The company's market cap stands at ₹2,031 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Vimta Labs Ltd stock opened at ₹426.85 and is currently trading at ₹439.45, showing a decline of ₹12.60 (2.79%). The intraday high is ₹445.95 and low is ₹424.9. The trading volume stands at 1,85,306 shares, indicating moderate market participation today.
Vimta Labs Ltd has a Price-to-Earnings (P/E) ratio of 25.83, which means investors are willing to pay ₹25.83 for every ₹1 of earnings. With an EPS of ₹17.47, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Vimta Labs Ltd has a market capitalization of ₹2,031 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹439.45) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Vimta Labs Ltd has a book value of ₹85.19 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹439.45, which is 415.8% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Vimta Labs Ltd has a Return on Equity (ROE) of 9.62% and Return on Capital Employed (ROCE) of 17.60%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Vimta Labs Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Vimta Labs Ltd has a debt-to-equity ratio of 0.02, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Vimta Labs Ltd has an Earnings Per Share (EPS) of ₹17.47, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹439.45 and P/E ratio of 25.83, investors are paying 25.83 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Vimta Labs Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Vimta Labs Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Vimta Labs Ltd stock, consider: 1) Fundamental Analysis - Review P/E (25.83), ROE (9.62%), debt-to-equity (0.02), and growth rates. 2) Technical Analysis - Check 52-week range (₹408.10 - ₹1173.85), moving averages, and chart patterns. 3) Valuation - Compare current price (₹439.45) with book value (₹85.19) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Vimta Labs Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹439.45 is 21873x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Vimta Labs Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹408.10 - ₹1173.85). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.02 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,85,306 shares. 5) Valuation Risk - P/E of 25.83 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Vimta Labs Ltd operates in the industry with key metrics: P/E ratio of 25.83, ROE of 9.62%, market cap of ₹2,031 crores, and dividend yield of 0.22%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.02), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Vimta Labs Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹439.45, with a 52-week range of ₹408.10 to ₹1173.85. Based on fundamentals like P/E (25.83), ROE (9.62%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Vimta Labs Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹439.45. 2) Fundamental Deterioration - Declining ROE (currently 9.62%), increasing debt (D/E: 0.02), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Vimta Labs Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.22%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.